Global Research Output in Vertigo: A Scientometric Analysis

AbstractBackgroundThis analysis uses the Scopus multidisciplinary online database to include research papers on vertigo from 2019 to 2025. The study’s objective is to investigate the growth of publications year after year, the relative growth rate and doubling time, the contributions of the top ten authors, document types, time series analysis, the contributions of the top ten journals, institutions, nations, languages, and highly cited papers in publications related to network security research.AimThis study studies or evaluates Vertigo research trends from 2016 to 2025 to discuss the possibility of employing data from the Scopus database. Between 2016 and 2025, there was an annual rise in Vertigo research articles of 6398 research publications, 13,174 citations research publications, the H-index is 57, the CPP is 24.90, and the RCI is 1.81 publications.ObjectivesTo perform a bibliometric analysis of the Global research output in Vertigo Research between 2016 and 2025. The authors’ study purpose is to look at how scientometric Vertigo research is evolving and to detect any trends in that development. It also intends to discover prior trends in Vertigo research publications published in scientometrics based on the sample data.MaterialThe relative growth rate is on the decline, according to this analysis. Concurrently, it was discovered that the doubling time was 0.75 in 2017 and 0.09 in 2025, confirming the pattern of rising doubling time. The United States contributed the most articles, with 1644 (30.82%) research publications, while Neuroscience contributed a maximum of 5803 (66.46%) research publications. The vast majority of the research output is available as Article 4804 (75.04%) research publications. Ludwig-Maximilians-Universität München alone generated 185 (17.96%) articles from its institutions, and Frontiers in Neurology topped the list with 263 (25.29%) publications, earning the top spot. The statistical application of time series analysis is anticipated to be approximately 7,498 in 2025 and 8,048 in 2030 in the Vertigo research publications. The paper with the most citations is Planchard, et al. (2016). An open-label, multicentre phase 2 trial of dabrafenib with trametinib in patients with metastatic non-small cell lung cancer that has been treated for BRAFV600E mutations was published in The Lancet Oncology (17(7): 984–993). Both the document type of the article and the number of citations total 765.